EyePoint Pharmaceuticals
EYPT

$7.97

1.12%

Market Cap: $427M

About: EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Employees: 144

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 45

0.91% less ownership

Funds ownership: 113.05% [Q1] → 112.14% (-0.91%) [Q2]

7% less funds holding

Funds holding: 162 [Q1] → 150 (-12) [Q2]

32% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 37

40% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 3 (-2) [Q2]

43% less call options, than puts

Call options by funds: $6.89M | Put options by funds: $12.1M

56% less capital invested

Capital invested by funds: $1.16B [Q1] → $508M (-$656M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

88%

upside

Avg. target

$26

220%

upside

High target

$30

276%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Jefferies Kambiz Yazdi 0% 1-year accuracy 0 / 4 met price target	88%upside $15	Buy Initiated	28 Aug 2024
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target	264%upside $29	Overweight Maintained	13 Aug 2024
Chardan Capital Daniil Gataulin 18% 1-year accuracy 3 / 17 met price target	251%upside $28	Buy Maintained	28 Jun 2024
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target	276%upside $30	Buy Reiterated	27 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about EYPT published over the past 30 days

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 -

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock, but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains.

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference:

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Zacks Investment Research

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.61 per share a year ago.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET.

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that Jay S.

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

See News Rankings